Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study is designed to test the hypothesis in healthy subjects that the oral antidiabetic drug rosiglitazone provides additional vascular relaxing or modulating effects in addition to its blood glucose level reducing ability.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Male

• Healthy

• 18 - 40 years old

• Non-smoker

• No additional medication

Exclusion Criteria:

• Any relevant disease

• Smokers

• Elevated liver enzymes

• Body weight different from Broca norm > 20%

• Allergies